BAXTER INTERNATIONAL INC

ISIN: US0718131099 WKN: 071813109 Asset Class: Stock



Company Profile

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets I	Liabilities and equity	
Current assets	9,600,000,000		8,011,000,000		8,872,000,000		
Common stock capital		683,000,000		683,000,000		683,000,000	
Fixed assets	18,676,000,000		20,276,000,000		24,649,000,000		
Equity capital of a company		8,468,000,000		5,895,000,000		9,121,000,000	
Cash and cash equivalents	3,198,000,000		1,722,000,000		2,956,000,000		
Accrued liabilities		959,000,000		906,000,000		1,092,000,000	
Other assets	-		-		-		
Current liabilities		6,503,000,000		4,745,000,000		4,236,000,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		13,305,000,000		17,647,000,000		20,164,000,000	
Different income		-		-		-	
Other liabilities		331,000,000		355,000,000		439,000,000	
Total assets	28,276,000,000	28,276,000,000	28,287,000,000	28,287,000,000	33,521,000,000	33,521,000,000	

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	60,000	60,000	60,000
Equity ratio	30.18%	21.06%	27.34%
Debt-equity ratio	231.33%	374.85%	265.75%

Others

	2023	2022	2021
Tax Expense Rate	33.01%	-2.89%	12.32%

BAXTER INTERNATIONAL INC

ISIN: US0718131099 WKN: 071813109 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	14,813,000,000	15,113,000,000	12,784,000,000
Net income	-76,000,000	-2,433,000,000	1,284,000,000
EBIT	327,420,000	-1,765,339,500	1,478,847,000
Operating income before taxes	-103,000,000	-2,353,000,000	1,477,000,000
Cash Flow	1,726,000,000	1,211,000,000	2,222,000,000
Net interest income	-463,000,000	-412,000,000	-149,000,000
Research and development expenses	655,000,000	602,000,000	529,000,000
Income taxes	-34,000,000	68,000,000	182,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	224,540	229,088	193,784

Board of Directors

Members of Management Board

D. Shafer	Member of Board of Directors
David Wilkes	Member of Board of Directors
Stephen Oesterle	Member of Board of Directors
Amy McBride-Wendell	Member of Board of Directors
Catherine Smith	Member of Board of Directors
Cathy Smith	Member of Board of Directors
Nancy Schlichting	Member of Board of Directors
Patricia Morrison	Member of Board of Directors
Peter Wilver	Member of Board of Directors
Stephen Rusckowski	Member of Board of Directors
William Ampofo	Member of Board of Directors
José (Joe) E. Almeida	Chairman of Managing Board
Gerard Greco	Member of Executive Committee
James W. Borzi	Member of Executive Committee
Jeanne Mason	Member of Executive Committee
Joel Grade	Member of Executive Committee
Talvis Love	Member of Executive Committee
Tobi Karchmer	Member of Executive Committee